{"drugs":["Krystexxa","Pegloticase"],"mono":{"0":{"id":"929695-s-0","title":"Generic Names","mono":"Pegloticase"},"1":{"id":"929695-s-1","title":"Dosing and Indications","sub":[{"id":"929695-s-1-4","title":"Adult Dosing","mono":"<ul><li>not recommended for the treatment of asymptomatic hyperuricemia<\/li><li>gout flare prophylaxis with an NSAID or colchicine one week before pegloticase initiation is recommended<\/li><li><b>Gout, Refractory to Conventional Therapy:<\/b> 8 mg IV over no less than 2 hours every 2 weeks; premedicate with antihistamines and corticosteroids<\/li><\/ul>"},{"id":"929695-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"929695-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dosage adjustment necessary<\/li><li><b>geriatric patients:<\/b> no dosage adjustment necessary<\/li><\/ul>"},{"id":"929695-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Gout, Refractory to Conventional Therapy<br\/>"}]},"2":{"id":"929695-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Anaphylaxis and infusion reactions have been reported to occur during and after administration of pegloticase. Pegloticase should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids and be closely monitored for an appropriate period of time for anaphylaxis after administration of pegloticase. Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg\/dL, particularly when 2 consecutive levels above 6 mg\/dL are observed.<br\/>"},"3":{"id":"929695-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929695-s-3-9","title":"Contraindications","mono":"glucose-6-phosphate dehydrogenase (G6PD) deficiency; risk of hemolysis and methemoglobinemia <br\/>"},{"id":"929695-s-3-10","title":"Precautions","mono":"<ul><li>anaphylaxis (eg, wheezing, perioral or lingual edema, or hemodynamic instability, with or without urticaria or rash), immediate (within 2 hours) or delayed, has been reported in patients who received pretreatment with oral antihistamine, IV corticosteroid, and\/or acetaminophen; increased risk in patients who lose therapeutic response (ie, uric acid levels above 6 mg\/dL); monitoring recommended; concomitant use of oral urate-lowering medications not recommended as it may blunt the rise of serum uric acid levels<\/li><li>anaphylaxis may occur with any pegloticase infusion, including the first infusion<\/li><li>infusion reactions (eg, urticaria, dyspnea, chest discomfort, chest pain, erythema and pruritus) have been reported in patients who have received pretreatment with oral antihistamine, IV corticosteroid, and\/or acetaminophen; increased risk with uric acid levels above 6 mg\/dL, especially with 2 consecutive levels above 6 mg\/dL; concomitant use of oral urate-lowering medications not recommended as it may blunt the rise of serum uric acid levels; monitoring recommended; rate adjustment or discontinuation of infusion may be necessary<\/li><li>concomitant use of oral urate-lowering therapy not recommended<\/li><li>congestive heart failure; risk of exacerbation<\/li><li>gout flare may occur following initiation of therapy; NSAID or colchicine prophylaxis is recommended<\/li><li>retreatment after a drug-free interval of more then 4 weeks; possible increased risk of anaphylaxis and infusion reactions due to immunogenicity<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929695-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"929695-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929695-s-4","title":"Drug Interactions","sub":{"1":{"id":"929695-s-4-14","title":"Major","mono":"<ul><li>Allopurinol (theoretical)<\/li><li>Oxypurinol (theoretical)<\/li><li>Probenecid (theoretical)<\/li><li>Sulfinpyrazone (theoretical)<\/li><\/ul>"}}},"5":{"id":"929695-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (6%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (6%), Nausea (12%), Vomiting (5%)<\/li><li><b>Musculoskeletal:<\/b>Gout, acute (first 3 months, 74% to 81%; last 3 months, 41% to 57%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis (4.8% to 6.5%)<\/li><li><b>Other:<\/b>Complication of infusion (26% to 41%)<\/li><\/ul>"},"6":{"id":"929695-s-6","title":"Drug Name Info","sub":{"0":{"id":"929695-s-6-17","title":"US Trade Names","mono":"Krystexxa<br\/>"},"2":{"id":"929695-s-6-19","title":"Class","mono":"<ul><li>Antigout<\/li><li>Enzyme<\/li><\/ul>"},"3":{"id":"929695-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929695-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929695-s-7","title":"Mechanism Of Action","mono":"Pegloticase is a PEGylated uric acid specific enzyme that lowers serum uric acid levels by catalyzing the oxidation of uric acid to allantoin, an inert and water soluble purine metabolite that is readily eliminated, primarily by renal excretion.<br\/>"},"9":{"id":"929695-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>dilute 8 mg (1 mL) in 250 mL NS or 0.45% NS; gently invert to mix (do not shake)<\/li><li>do not mix or dilute with other drugs<\/li><li>store diluted solution under refrigeration (recommended) at 2 to 8 degrees C (36 to 46 degrees F) or at room temperature (20 to 25 degrees C; 68 to 77 degrees F); use within 4 hours<\/li><li>protect diluted solution from light; do not freeze<\/li><li>do not administer as IV push or IV bolus<\/li><li>allow diluted solution to reach room temperature before infusion<\/li><li>administer by IV infusion over no less than 2 hours via gravity feed, syringe-type pump, or infusion pump<\/li><li>slow, interrupt and restart at lower rate, or discontinue infusion if an infusion reaction develops<\/li><\/ul>"},"10":{"id":"929695-s-10","title":"Monitoring","mono":"<ul><li>serum uric acid level less than 6 mg\/dL is indicative of efficacy<\/li><li>serum uric acid levels prior to each infusion<\/li><li>glucose-6-phosphate dehydrogenase (G6PD) deficiency screening, baseline; in patients at high risk of G6PD deficiency (eg, patients of African or Mediterranean decent)<\/li><li>signs and symptoms of anaphylaxis or infusion reactions<\/li><li>signs and symptoms of congestive heart failure exacerbation<\/li><\/ul>"},"11":{"id":"929695-s-11","title":"How Supplied","mono":"<b>Krystexxa<\/b><br\/>Intravenous Solution: 8 MG\/ML<br\/>"},"13":{"id":"929695-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause gout flares, chest pain, nausea, constipation, contusion or ecchymosis, nasopharyngitis, and vomiting.<\/li><li>Advise patient to report signs\/symptoms of infusion reaction (eg, urticaria, erythema, dyspnea, flushing, rash, and chest pain or discomfort) or anaphylaxis (eg, wheezing, perioral or lingual edema, rash, and urticaria).<\/li><\/ul>"}}}